Yes. Blue Cross Blue Shield of Massachusetts covers Spravato (esketamine) for treatment-resistant depression when prior authorization criteria are met. BCBS MA's PA criteria under Medical Policy 087 are among the strictest published thresholds of any major Massachusetts payer — requiring four failed antidepressant trials plus at least one augmenting-agent trial.
Across Lumin Health's 2026 commercial Spravato (esketamine) authorizations: 100% approval rate, with a median 4-day decision turnaround. Lumin Health's pre-submission medical-necessity review and standardized clinical documentation packet contribute to this outcome. Individual approval depends on plan-specific PA criteria — see BCBS MA's policy summary below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
Blue Cross Blue Shield of Massachusetts covers Spravato for adults with treatment-resistant major depressive disorder when all of the following are documented (per BCBS MA Medical Policy 087, last reviewed January 2026):
For major depressive disorder with acute suicidal ideation or behavior, BCBS MA applies separate criteria allowing up to 28 days of initial coverage; the MDD-SI pathway requires the patient to be currently hospitalized.
Submission method. Submit via the BCBS MA Authorization Manager portal (primary) using the Prior Authorization Request Form for Esketamine Nasal Spray (Spravato) and Intravenous Ketamine (Form 094). Out-of-network providers fax to 1-888-641-5199. Inpatient services require precertification.
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine. BCBS MA Policy 087 covers both Spravato and IV ketamine under the same medical-necessity criteria; if you're researching IV ketamine coverage under BCBS MA, that section of Policy 087 does not apply to Lumin Health's services.
Massachusetts requires commercial insurers to cover mental health services on parity with medical/surgical benefits under Chapter 175 Section 47B and federal MHPAEA. This means Blue Cross Blue Shield of Massachusetts cannot apply more restrictive prior authorization, visit limits, or cost-sharing to Spravato than to comparable medical treatments. For Massachusetts Medicaid (MassHealth) members, Spravato coverage follows the MassHealth Drug List criteria, which differ from commercial; Lumin Health verifies your specific plan at consultation.
Two Massachusetts statutes are particularly relevant when a commercial insurer reviews a Spravato prior authorization:
The “deemed granted” rule. Under 211 CMR 52.07, a Massachusetts commercial carrier that fails to respond to a complete prior authorization request within two business days is deemed to have granted the authorization. This applies to all major Massachusetts commercial carriers — Aetna, Blue Cross Blue Shield of Massachusetts, Cigna, Harvard Pilgrim Health Care, Mass General Brigham Health Plan, UnitedHealthcare, and the Group Insurance Commission's contracted carriers.
External review through the Office of Patient Protection. If your commercial insurer denies a Spravato authorization, you have the right to request external review by the Health Policy Commission's Office of Patient Protection (OPP). The filing window is four months from the final internal denial; OPP issues decisions within 45 days. Historically, more than 40% of OPP external reviews resolve in the patient's favor — an unusually patient-favorable rate compared with most states' insurance-department-administered review processes.
Lumin Health's Newton, Cambridge, Woburn, and Brookline locations handle BCBS MA Spravato authorizations end-to-end.
Spravato treatment at Lumin Health is available at all four Massachusetts locations: Newton, Cambridge, Woburn, and Brookline. All Lumin Health Spravato locations are REMS-certified per FDA requirements.
How BCBS MA compares with other major Massachusetts commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes — BCBS MA requires PA submitted via the Authorization Manager portal using the dedicated Esketamine/Ketamine Prior Authorization Request Form (Form 094). Out-of-network providers fax to 1-888-641-5199. Inpatient services require precertification.
Four antidepressants from at least two different classes, each at generally accepted therapeutic doses for at least 6 weeks with ≥80% adherence — plus at least one trial of an augmenting agent (atypical antipsychotic, lithium, or thyroid hormone T3). Per Policy 087, the augmenting-agent trial is a hard requirement bundled with the four AD trials — not optional.
In Lumin's typical experience, complete BCBS MA submissions receive decisions within 24–48 hours.
Lumin Health handles everything on your behalf so you don't have to worry. If your prior authorization is denied, our team manages the appeal process directly with BCBS Massachusetts — you don't need to navigate the paperwork or follow-ups.
Initial authorization covers up to 28 days for the induction phase; continuation phase may be authorized for up to 1 year when documented improvement on a validated depression rating scale is shown. Per Policy 087, continuation therapy beyond 12 months for TRD is considered investigational and non-covered.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from the date of treatment, event, or circumstance giving rise to the dispute (per BCBS MA: "All requests for an appeal or a grievance review must be received by Blue Cross Blue Shield HMO Blue within 180 calendar days of the date of treatment, event, or circumstance which is the cause of your dispute or complaint."). Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Member Grievance Program, Blue Cross Blue Shield of Massachusetts, One Enterprise Drive, Quincy, MA 02171-2126. Phone: 1-800-462-5601, ext. 63605. Fax: 1-617-246-3616. Email: grievances@bcbsma.com.
Step 2 — Peer-to-peer (P2P) review. BCBS MA does offer peer-to-peer review at the precertification stage; the pathway is documented in the BCBS MA provider manual. Your prescriber contacts the BCBS MA medical reviewer named in the denial letter to request a P2P. For appeal-stage clinical review, include a written request for peer-to-peer with the appeal submission.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), BCBS MA must resolve urgent internal appeals within 72 hours. Member or treating physician requests expedited review by calling 1-800-462-5601, ext. 63605, and documenting medical urgency.
Appeal levels. BCBS MA generally provides a single internal appeal level for commercial members, with the right to external review through the Office of Patient Protection thereafter. Verify levels on your specific plan summary.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Behavioral health benefits at BCBS MA are administered in-house for most commercial plans (not vendored to Optum/Magellan/Carelon), so Spravato appeals follow the same Member Grievance Program pathway as any other clinical denial. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Blue Cross Blue Shield of Massachusetts medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from the date of treatment, event, or circumstance giving rise to the dispute (per BCBS MA: "All requests for an appeal or a grievance review must be received by Blue Cross Blue Shield HMO Blue within 180 calendar days of the date of treatment, event, or circumstance which is the cause of your dispute or complaint."). Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Member Grievance Program, Blue Cross Blue Shield of Massachusetts, One Enterprise Drive, Quincy, MA 02171-2126. Phone: 1-800-462-5601, ext. 63605. Fax: 1-617-246-3616. Email: grievances@bcbsma.com.
Step 2 — Peer-to-peer (P2P) review. BCBS MA does offer peer-to-peer review at the precertification stage; the pathway is documented in the BCBS MA provider manual. Your prescriber contacts the BCBS MA medical reviewer named in the denial letter to request a P2P. For appeal-stage clinical review, include a written request for peer-to-peer with the appeal submission.
Step 3 — Expedited (urgent) appeal. Under Massachusetts state mandate (211 CMR 52), BCBS MA must resolve urgent internal appeals within 72 hours. Member or treating physician requests expedited review by calling 1-800-462-5601, ext. 63605, and documenting medical urgency.
Appeal levels. BCBS MA generally provides a single internal appeal level for commercial members, with the right to external review through the Office of Patient Protection thereafter. Verify levels on your specific plan summary.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Behavioral health benefits at BCBS MA are administered in-house for most commercial plans (not vendored to Optum/Magellan/Carelon), so Spravato appeals follow the same Member Grievance Program pathway as any other clinical denial. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Blue Cross Blue Shield of Massachusetts medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
